Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
PRINCETON, N.J., April 16, 2013 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, today announced the closing of its previously-announced initial public offering of 8,000,000 shares of its common stock at $8.00 per share. Omthera's common stock is listed on the NASDAQ Global Market under the trading symbol "OMTH". All shares of common stock were offered by Omthera Pharmaceuticals, Inc.
BofA Merrill Lynch, Barclays and Leerink Swann acted as joint book-running managers for the offering; Stifel and Piper Jaffray served as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 11, 2013. The offering was made only by means of a prospectus, copies of which may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at firstname.lastname@example.org, from Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847, or by emailing email@example.com, or from Leerink Swann, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by calling (800) 808-7525 ext. 4814.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. (the "Company") is an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for dyslipidemia and the treatment of cardiovascular disease. Epanova, currently the Company's sole product candidate, is a late-stage, novel, omega-3 free fatty acid composition that meaningfully reduces triglycerides, improves other key lipid parameters and is expected to increase patient convenience with 2-gram once-a-day dosing with or without meals. Epanova is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-3 and omega-6 fatty acids, with EPA, DHA, and docosapentaenoic acid being the most abundant forms of omega-3 fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product.
Omthera maintains a website at www.omthera.com.
Executive Vice President & Chief Financial Officer
SOURCE Omthera Pharmaceuticals, Inc.